Chief Executive Officer
Cynthia (Cindy) Collins, CEO, Human Longevity, has more than 35 years of experience in leading global teams in diagnostic, life sciences, and biopharm businesses. Most recently she served as the CEO/GM of GE Healthcare’s Cell Therapy and Lab Businesses as well as CEO, Clarient Diagnostics, Inc. Prior to joining GE, she served as President and CEO of GenVec, Inc., a publicly-traded biopharmaceutical company focused on developing gene therapies and vaccines. Prior to that, Ms. Collins served as Group Vice President, Cellular Analysis Business (Coulter) of Beckman Coulter until its sale to Danaher in 2011. Prior to joining Beckman Coulter, Ms. Collins served as President and CEO of Sequoia Pharmaceuticals, Inc., a private biotechnology company developing antiviral drugs for HIV and HCV. Before joining Sequoia Pharmaceuticals, Ms. Collins served as President of Clinical Micro Sensors, Inc., a wholly owned subsidiary of Motorola (now GenMark Diagnostics) where she directed the development and commercialization of molecular diagnostic products and led the eventual strategic divestiture of the division. Before Motorola, she spent over 17 years at Baxter Healthcare in a variety of executive roles, including President of Oncology, Vice President of Strategy and Portfolio Management of BioScience, Vice President & General Manager of Cell Therapies, and Vice President of Business Development of Transfusion Therapies . Prior to joining Baxter Healthcare, she worked six years in the Diagnostics Division of Abbott Laboratories. Ms. Collins received her BS degree in Microbiology from the University of Illinois, Urbana and her MBA, with a specialization in marketing, from The University of Chicago Booth School of Business.
Ms. Collins is a member of the board of directors for the Analytical Life Science and Diagnostics Association and a strategic advisor to Phase Holographic Imaging, Lund, Sweden.